{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigmlin6um3rq5pnx6wssrmon3lqqknmukltevwprfrwkl73axnk4m",
    "uri": "at://did:plc:3ueatpf6zh5nibd6nd3pao4o/app.bsky.feed.post/3mnsg34aqg2s2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicds5r5brpmxtapxm2cv3f4yuwzborxi7ganfbthrynnf27h4phie"
    },
    "mimeType": "image/webp",
    "size": 156406
  },
  "path": "/novo-nordisk-ceo-looks-beyond-weight-loss-longevity-aesthetics/",
  "publishedAt": "2026-06-08T15:13:12.000Z",
  "site": "https://athletechnews.com",
  "tags": [
    "Industry News",
    "GLP-1",
    "Longevity",
    "Novo Nordisk"
  ],
  "textContent": "Novo Nordisk's CEO says the company’s blockbuster obesity drugs could ultimately pull it into increasingly buzzy areas of healthcare, from longevity research to aesthetic medicine.",
  "title": "Novo Nordisk CEO Looks Beyond Weight Loss to Longevity and Aesthetics"
}